Cargando…
Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study
PURPOSE: In patients with esophageal cancer (EC), intensity modulated radiation therapy (IMRT) improves dose sparing to the heart and lung, with some evidence showing clinical benefit. Herein, we report our cumulative clinical experience with the use of IMRT for EC. METHODS AND MATERIALS: This is a...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605282/ https://www.ncbi.nlm.nih.gov/pubmed/29114598 http://dx.doi.org/10.1016/j.adro.2017.04.002 |
_version_ | 1783264959816269824 |
---|---|
author | Shi, Anhui Liao, Zhongxing Allen, Pamela K. Ho, Linus Murphy, Mariela Blum Maru, Dipen M. Swisher, Stephen G. Hofstetter, Wayne L. Mehran, Reza J. Cox, James D. Komaki, Ritsuko Lin, Steven H. |
author_facet | Shi, Anhui Liao, Zhongxing Allen, Pamela K. Ho, Linus Murphy, Mariela Blum Maru, Dipen M. Swisher, Stephen G. Hofstetter, Wayne L. Mehran, Reza J. Cox, James D. Komaki, Ritsuko Lin, Steven H. |
author_sort | Shi, Anhui |
collection | PubMed |
description | PURPOSE: In patients with esophageal cancer (EC), intensity modulated radiation therapy (IMRT) improves dose sparing to the heart and lung, with some evidence showing clinical benefit. Herein, we report our cumulative clinical experience with the use of IMRT for EC. METHODS AND MATERIALS: This is a retrospective analysis of 587 patients with nonmetastatic EC who were treated consecutively with IMRT from January 2004 to June 30, 2013. All patients with stage I-IVA (American Joint Committee on Cancer 2002) received concurrent chemoradiation therapy either preoperatively or definitively. The Kaplan-Meier method was used to compute overall survival (OS) and locoregional recurrence-free survival and disease-free survival. The Common Terminology Criteria for Adverse Events, Version 4.0 were used to grade acute and subacute complications. RESULTS: The median radiation dose was 50.4 Gy in 28 daily fractions. As of July 2015, the median follow-up was 31.4 months (range, 2.9-130.7 months) for all patients and 61.8 months (range, 7.7-130.7 months) for survivors. The median OS was 38.9 months, and the 1-, 3-, and 5-year OS rates were 86.7%, 51.8%, and 41.2%, respectively. The 1-, 3-, and 5-year locoregional recurrence-free survival rates were 77.6%, 68.2%, and 66.1%, respectively, and the 1-, 3-, and 5-year disease-free survival rates were 58.6%, 43.7%, and 41.4%, respectively. Outcomes for both trimodality and bimodality treated patients were better than the outcomes reported in the literature. Eight patients (1.4%) experienced grade ≥3 pneumonitis, and 74 patients (13%) developed grade ≥3 esophagitis. For patients who underwent surgery, the most common postoperative complications were pneumonia (9.6%), anastomotic leakage (11.1%), and atrial fibrillation (12.5%). CONCLUSIONS: This is the largest, single institutional study to date on the long-term outcomes of treatment with IMRT for EC. For photon-based radiation therapy, IMRT yields excellent outcomes and should be considered for the treatment of EC. |
format | Online Article Text |
id | pubmed-5605282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-56052822017-11-07 Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study Shi, Anhui Liao, Zhongxing Allen, Pamela K. Ho, Linus Murphy, Mariela Blum Maru, Dipen M. Swisher, Stephen G. Hofstetter, Wayne L. Mehran, Reza J. Cox, James D. Komaki, Ritsuko Lin, Steven H. Adv Radiat Oncol Scientific Article PURPOSE: In patients with esophageal cancer (EC), intensity modulated radiation therapy (IMRT) improves dose sparing to the heart and lung, with some evidence showing clinical benefit. Herein, we report our cumulative clinical experience with the use of IMRT for EC. METHODS AND MATERIALS: This is a retrospective analysis of 587 patients with nonmetastatic EC who were treated consecutively with IMRT from January 2004 to June 30, 2013. All patients with stage I-IVA (American Joint Committee on Cancer 2002) received concurrent chemoradiation therapy either preoperatively or definitively. The Kaplan-Meier method was used to compute overall survival (OS) and locoregional recurrence-free survival and disease-free survival. The Common Terminology Criteria for Adverse Events, Version 4.0 were used to grade acute and subacute complications. RESULTS: The median radiation dose was 50.4 Gy in 28 daily fractions. As of July 2015, the median follow-up was 31.4 months (range, 2.9-130.7 months) for all patients and 61.8 months (range, 7.7-130.7 months) for survivors. The median OS was 38.9 months, and the 1-, 3-, and 5-year OS rates were 86.7%, 51.8%, and 41.2%, respectively. The 1-, 3-, and 5-year locoregional recurrence-free survival rates were 77.6%, 68.2%, and 66.1%, respectively, and the 1-, 3-, and 5-year disease-free survival rates were 58.6%, 43.7%, and 41.4%, respectively. Outcomes for both trimodality and bimodality treated patients were better than the outcomes reported in the literature. Eight patients (1.4%) experienced grade ≥3 pneumonitis, and 74 patients (13%) developed grade ≥3 esophagitis. For patients who underwent surgery, the most common postoperative complications were pneumonia (9.6%), anastomotic leakage (11.1%), and atrial fibrillation (12.5%). CONCLUSIONS: This is the largest, single institutional study to date on the long-term outcomes of treatment with IMRT for EC. For photon-based radiation therapy, IMRT yields excellent outcomes and should be considered for the treatment of EC. Elsevier 2017-04-19 /pmc/articles/PMC5605282/ /pubmed/29114598 http://dx.doi.org/10.1016/j.adro.2017.04.002 Text en © 2017 The Authors on behalf of the American Society for Radiation Oncology http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Scientific Article Shi, Anhui Liao, Zhongxing Allen, Pamela K. Ho, Linus Murphy, Mariela Blum Maru, Dipen M. Swisher, Stephen G. Hofstetter, Wayne L. Mehran, Reza J. Cox, James D. Komaki, Ritsuko Lin, Steven H. Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study |
title | Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study |
title_full | Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study |
title_fullStr | Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study |
title_full_unstemmed | Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study |
title_short | Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study |
title_sort | long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: a large single-institutional cohort study |
topic | Scientific Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605282/ https://www.ncbi.nlm.nih.gov/pubmed/29114598 http://dx.doi.org/10.1016/j.adro.2017.04.002 |
work_keys_str_mv | AT shianhui longtermsurvivalandtoxicityoutcomesofintensitymodulatedradiationtherapyforthetreatmentofesophagealcanceralargesingleinstitutionalcohortstudy AT liaozhongxing longtermsurvivalandtoxicityoutcomesofintensitymodulatedradiationtherapyforthetreatmentofesophagealcanceralargesingleinstitutionalcohortstudy AT allenpamelak longtermsurvivalandtoxicityoutcomesofintensitymodulatedradiationtherapyforthetreatmentofesophagealcanceralargesingleinstitutionalcohortstudy AT holinus longtermsurvivalandtoxicityoutcomesofintensitymodulatedradiationtherapyforthetreatmentofesophagealcanceralargesingleinstitutionalcohortstudy AT murphymarielablum longtermsurvivalandtoxicityoutcomesofintensitymodulatedradiationtherapyforthetreatmentofesophagealcanceralargesingleinstitutionalcohortstudy AT marudipenm longtermsurvivalandtoxicityoutcomesofintensitymodulatedradiationtherapyforthetreatmentofesophagealcanceralargesingleinstitutionalcohortstudy AT swisherstepheng longtermsurvivalandtoxicityoutcomesofintensitymodulatedradiationtherapyforthetreatmentofesophagealcanceralargesingleinstitutionalcohortstudy AT hofstetterwaynel longtermsurvivalandtoxicityoutcomesofintensitymodulatedradiationtherapyforthetreatmentofesophagealcanceralargesingleinstitutionalcohortstudy AT mehranrezaj longtermsurvivalandtoxicityoutcomesofintensitymodulatedradiationtherapyforthetreatmentofesophagealcanceralargesingleinstitutionalcohortstudy AT coxjamesd longtermsurvivalandtoxicityoutcomesofintensitymodulatedradiationtherapyforthetreatmentofesophagealcanceralargesingleinstitutionalcohortstudy AT komakiritsuko longtermsurvivalandtoxicityoutcomesofintensitymodulatedradiationtherapyforthetreatmentofesophagealcanceralargesingleinstitutionalcohortstudy AT linstevenh longtermsurvivalandtoxicityoutcomesofintensitymodulatedradiationtherapyforthetreatmentofesophagealcanceralargesingleinstitutionalcohortstudy |